Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 751 to 765 of 1553 results for do not do recommendations

  1. Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)

    Evidence-based recommendations on carfilzomib (Kyprolis) with dexamethasone and lenalidomide (Revlimid) for previously treated multiple myeloma in adults.

    Technology appraisal guidance
    Published
    28 April 2021
    View recommendations

    Sections for TA695

  2. Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)

    Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.

    Technology appraisal guidance
    Published
    4 June 2015
    View recommendations

    Sections for TA341

  3. Guide to the technology appraisal and highly specialised technologies appeal process (pre June 2023) (PMG18)

    This document concerns the appeal process for the technology appraisal and highly specialised technologies programmes and provides an overview for organisations wishing to lodge an appeal

  4. SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea (HTG598)

    Evidence-based recommendations on SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea.

    HealthTech guidance
    Published
    17 November 2021
    View recommendations

    Sections for HTG598

  5. Roflumilast for treating chronic obstructive pulmonary disease (TA461)

    Evidence-based recommendations on roflumilast (Daxas) for treating chronic obstructive pulmonary disease in adults with chronic bronchitis.

    Technology appraisal guidance
    Published
    26 July 2017
    View recommendations

    Sections for TA461

  6. Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease.

    Technology appraisal guidance
    Published
    17 October 2019
    View recommendations

    Sections for TA607

  7. Motivating dental practice teams to take a preventive approach:- What would motivate dental practice teams to take a preventive approach to oral health – especially with high risk groups – and how does this fit into the dental practice business model?

    Recommendation ID NG30/5 Question Motivating dental practice teams to take a preventive approach:- What would motivate dental practice

    Research recommendation
    Published
    28 January 2016

  8. Self-management:- Do structured psoriasis-focused self-management programmes improve patient confidence, wellbeing and disease control compared with standard care?

    Recommendation ID CG153/4 Question Self-management:- Do structured psoriasis-focused self-management programmes improve...

    Research recommendation
    Published
    9 June 2015

  9. Monitoring pulmonary disease:- Is lung clearance index a useful and cost-effective tool for the routine assessment and monitoring of changes in pulmonary status in people with cystic fibrosis?

    Recommendation ID NG78/3 Question Monitoring pulmonary disease:- Is lung clearance index a useful and cost-effective tool for the routine

    Research recommendation
    Published
    6 November 2018

  10. AEDs and pregnancy: What is the malformation rate and longer term neurodevelopmental outcome of children born to mothers who have taken AEDs during pregnancy?

    Recommendation ID CG137/5 Question AEDs and pregnancy: What is the malformation rate and longer term neurodevelopmental outcome of...

    Research recommendation
    Published
    13 August 2021

  11. Adding a newer anti-anginal drug to a calcium channel blocker:- What is the clinical and cost effectiveness of adding a newer anti-anginal drug (nicorandil, ivabradine or ranolazine) to a calcium channel blocker for treating stable angina?

    Recommendation ID CG126/1 Question Adding a newer anti-anginal drug to a calcium channel blocker:- What is the clinical and cost...

    Research recommendation
    Published
    9 June 2015

  12. Can GP practices deliver effective and cost effective condom schemes to reduce STIs?: -Can condom schemes be effective and cost effective in GP practices to reduce STIs? Can they be delivered in ways that are acceptable to GPs and other practice staff? In addition, how can the impact of such schemes be maximised?

    Recommendation ID NG68/5 Question Can GP practices deliver effective and cost effective condom schemes to reduce STIs?: -Can condom...

    Research recommendation
    Published
    12 October 2018

  13. Clean air zones:- How do different elements of a clean air zone interact to improve air quality and what is the overall effect on people's health?

    Recommendation ID NG70/3 Question Clean air zones:- How do different elements of a clean air zone interact to improve air...

    Research recommendation
    Published
    12 October 2018

  14. Supporting young people to manage their conditions:- What is the relationship between transition and subsequent self-management?

    Recommendation ID NG43/6 Question Supporting young people to manage their conditions:- What is the relationship between transition and

    Research recommendation
    Published
    21 March 2016

  15. Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor (TA1062)

    Evidence-based recommendations on erdafitinib (Balversa) for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor in adults.

    Technology appraisal guidance
    Published
    12 May 2025

    Sections for TA1062